Spots Global Cancer Trial Database for refractory leukemia
Every month we try and update this database with for refractory leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia | NCT05870995 | Refractory Leuk... | CALGE-VEN- RIC-... | 16 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL | NCT05495035 | Lymphoblastic L... Leukemia, Lymph... Relapsed Leukem... Refractory Leuk... | Olverembatinib,... | 1 Year - 18 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | NCT06006403 | Acute Myeloid L... Blastic Plasmac... Relapse Leukemi... Refractory Leuk... | CD123 targeted ... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia | NCT05870995 | Refractory Leuk... | CALGE-VEN- RIC-... | 16 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia | NCT05043571 | Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... CAR CAR T-Cell-Rela... Refractory Leuk... | CAR T-cell ther... | 6 Months - 65 Years | National University Hospital, Singapore | |
| Decitabine, Cytarabine, GCSF for Refractory AML/MDS | NCT00740181 | Myelodysplasia Leukemia | chemotherapy | 19 Years - | Brown University | |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | NCT04065399 | Acute Myeloid L... Acute Lymphobla... Mixed Lineage A... Mixed Phenotype... Acute Leukemia ... | revumenib cobicistat | 30 Days - | Syndax Pharmaceuticals | |
| ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL | NCT02787369 | Recurrent Chron... | ACY-1215 Ibrutinib Idelalisib | 18 Years - | Dana-Farber Cancer Institute | |
| ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia | NCT01478074 | Acute Myeloid L... | G-CSF Cytarabine Fludarabine Donor Natural K... ALT-801 | 2 Years - 59 Years | Altor BioScience | |
| Decitabine, Cytarabine, GCSF for Refractory AML/MDS | NCT00740181 | Myelodysplasia Leukemia | chemotherapy | 19 Years - | Brown University | |
| Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients | NCT04597086 | Acute Leukemia Recurrent Leuke... Refractory Leuk... | Best Practice Bright White Li... Survey Administ... | - | Ohio State University Comprehensive Cancer Center | |
| Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children | NCT02512926 | Relapsed Solid ... Refractory Soli... Relapsed Leukem... Refractory Leuk... | Carfilzomib Cyclophosphamid... Etoposide | 6 Months - 29 Years | Stanford University | |
| Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy | NCT04282811 | Chronic Lymphoc... Relapse Leukemi... Refractory Leuk... | Venetoclax | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies | NCT04470947 | Advanced Lympho... Refractory Lymp... Refractory Leuk... Refractory Acut... Refractory T-Ce... | Next generation... Comprehensive g... | 18 Years - | Medical University of Vienna | |
| Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | NCT02215629 | Relapsed or Ref... Relapsed or Ref... | VS-4718 | 18 Years - | Verastem, Inc. | |
| Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia | NCT05576532 | T-lymphoblastic... Relapsed Diseas... Refractory Lymp... Refractory Leuk... Safety Efficacy, Self | BCL2 Inhibitor ... | 14 Years - 45 Years | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | |
| Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL | NCT05495035 | Lymphoblastic L... Leukemia, Lymph... Relapsed Leukem... Refractory Leuk... | Olverembatinib,... | 1 Year - 18 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL | NCT02787369 | Recurrent Chron... | ACY-1215 Ibrutinib Idelalisib | 18 Years - | Dana-Farber Cancer Institute | |
| Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | NCT02215629 | Relapsed or Ref... Relapsed or Ref... | VS-4718 | 18 Years - | Verastem, Inc. | |
| Tegavivint for the Treatment of Relapsed or Refractory Leukemia | NCT04874480 | Recurrent Leuke... Refractory Leuk... | Decitabine Tegavivint | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome | NCT00676728 | Advanced or Ref... Myelodysplastic... | JNJ-26481585 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Tegavivint for the Treatment of Relapsed or Refractory Leukemia | NCT04874480 | Recurrent Leuke... Refractory Leuk... | Decitabine Tegavivint | 18 Years - | M.D. Anderson Cancer Center | |
| Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | NCT02215629 | Relapsed or Ref... Relapsed or Ref... | VS-4718 | 18 Years - | Verastem, Inc. | |
| ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL | NCT02787369 | Recurrent Chron... | ACY-1215 Ibrutinib Idelalisib | 18 Years - | Dana-Farber Cancer Institute | |
| Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies | NCT04684472 | Refractory B-Ce... Refractory Leuk... | Modified anti-C... | 18 Years - 70 Years | Sichuan University | |
| Solving Riddles Through Sequencing | NCT05046444 | Leukemia Hematologic Mal... Rare Diseases Refractory Leuk... Refractory Lymp... Unknown Primary... | Next Generation... | 18 Years - 99 Years | Munich Leukemia Laboratory | |
| JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia | NCT00860522 | Leukemia | JVRS-100 JVRS-100 | 18 Years - | Milton S. Hershey Medical Center | |
| Study of Radiolabeled Revumenib in Adults With Acute Leukemia | NCT05406817 | Acute Leukemia | Revumenib | 18 Years - | Syndax Pharmaceuticals | |
| Study of Radiolabeled Revumenib in Adults With Acute Leukemia | NCT05406817 | Acute Leukemia | Revumenib | 18 Years - | Syndax Pharmaceuticals | |
| Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies | NCT04470947 | Advanced Lympho... Refractory Lymp... Refractory Leuk... Refractory Acut... Refractory T-Ce... | Next generation... Comprehensive g... | 18 Years - | Medical University of Vienna | |
| Solving Riddles Through Sequencing | NCT05046444 | Leukemia Hematologic Mal... Rare Diseases Refractory Leuk... Refractory Lymp... Unknown Primary... | Next Generation... | 18 Years - 99 Years | Munich Leukemia Laboratory | |
| Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients | NCT04597086 | Acute Leukemia Recurrent Leuke... Refractory Leuk... | Best Practice Bright White Li... Survey Administ... | - | Ohio State University Comprehensive Cancer Center | |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | NCT06006403 | Acute Myeloid L... Blastic Plasmac... Relapse Leukemi... Refractory Leuk... | CD123 targeted ... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | NCT05164042 | Relapse Leukemi... Refractory Leuk... | Allogeneic CD19... | 14 Years - 70 Years | Shenzhen University General Hospital | |
| Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia | NCT00391560 | Leukemia | perifosine | 18 Years - | AEterna Zentaris | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
